- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Niraparib Individualized Starting Dose Tolerable in Platinum-Sensitive Recurrent Ovarian Cancer
June 5th 2021, 4:41pm
Niraparib, when delivered at an individualized starting dose, was found to be well tolerated in patients with platinum-sensitive recurrent ovarian cancer.
Mosunetuzumab-Polatuzumab Vedotin Combo Effective, Well Tolerated in R/R B-NHL
June 5th 2021, 4:35pm
Two cases of cytokine release syndrome occurred during the first cycle of step-up dosing; however, both were considered non-severe and were treated without the need of tocilizumab, admission to the ICU or use of vasopressors.
First-Line Ibrutinib Yields 7-Year Survival Benefit in CLL
June 5th 2021, 4:03pm
Single-agent ibrutinib given in the first-line setting sustained a progression-free survival and overall survival benefit compared with chlorambucil as therapy for patients with chronic lymphocytic leukemia at 7-year follow-up.
Zenocutuzumab Demonstrates Clinical Activity in a Variety of NRG1+ Cancers
June 5th 2021, 2:59pm
Zenocutuzumab represents a promising novel targeted therapeutic option for patients with NRG1 fusion–positive cancers.
Aumolertinib Prolongs Survival, Duration of Response in NSCLC
June 5th 2021, 2:30pm
Treatment with aumolertinib was associated with prolonged survival and duration of response in patients with non–small cell lung cancer.
Triplet Combination Safe, Effective for Relapsed/Refractory DLBCL
June 5th 2021, 2:15pm
Patients with relapsed/refractory diffuse large B-cell lymphoma treated with a novel combination of polatuzumab vetodin, rituximab and lenalidomide contributed to an improved overall response and complete response, with 82% remaining in remission at the study’s cutoff date.
Dr. Bonvalot on the Long-Term Safety of NBTXR3 Plus Radiotherapy in Locally Advanced Soft Tissue Sarcoma
June 5th 2021, 1:36am
Sylvie Bonvalot, MD, PhD, HDR, discusses the long-term safety of NBTXR3 plus radiotherapy in patients with locally advanced soft tissue sarcoma who were treated in the phase 2/3 Act.In.Sarc trial.
Allogeneic HCT Plus Reduced Intensity Conditioning With Bortezomib Triplet Is Safe in Multiple Myeloma
June 5th 2021, 1:30am
Allogeneic hematopoietic cell transplantation was safe when used with a reduced-intensity conditioning regimen of bortezomib, fludarabine, and melphalan in patients with high-risk multiple myeloma.
Sotorasib Impresses With Durable Clinical Benefit in KRAS p.G12C+ NSCLC
June 5th 2021, 12:51am
Sotorasib provided continued durable clinical benefit in patients with pretreated KRAS p.G12C–mutated non–small cell lung cancer.
Brexucabtagene Autoleucel Induces High, Durable Responses in Heavily Pretreated Relapsed/Refractory B-ALL
June 5th 2021, 12:29am
A single infusion of brexucabtagene autoleucel, a CAR T-cell therapy, demonstrated robust and durable responses in heavily pretreated patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Amivantamab/Lazertinib Yields Durable Responses in Osimertinib-Relapsed, Chemo-Naïve EGFR+ NSCLC
June 5th 2021, 12:09am
Amivantamab in combination with lazertinib elicited responses in more than one-third of chemotherapy-naïve patients with EGFR-mutant non–small cell lung cancer who had progressed on osimertinib.
Lifileucel/Pembrolizumab Elicits Encouraging ORR in ICI-Naïve Advanced Melanoma
June 4th 2021, 11:39pm
The addition of lifileucel to pembrolizumab resulted in an overall response rate of 85.7% compared with pembrolizumab alone in patients with immune checkpoint inhibitor–naïve advanced melanoma.
Afami-cel Elicits Durable Response Rates in Patients With Synovial Sarcoma or MRCLS
June 4th 2021, 11:25pm
Encouraging initial durability has been observed with afamitresgene autoleucel in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma, according to data from the phase 2 SPEARHEAD-1 trial.
Patritumab Deruxtecan Displays Durable Efficacy in EGFR TKI–Resistant EGFR+ NSCLC
June 4th 2021, 11:20pm
Patritumab deruxtecan was found to induce clinically meaningful, durable efficacy in heavily pretreated patients with EGFR-mutated non–small cell lung cancer who were resistant to EGFR TKIs.
Catequentinib Shows Promise in Treatment of Advanced Synovial Sarcoma
June 4th 2021, 10:57pm
Catequentinib improved disease control and progression-free survival in patients with advanced synovial sarcoma compared with dacarbazine.
Dr. Skoulidis on the Results of Subgroup Analyses of the CodeBreaK 100 Trial in KRAS G12C-Mutant NSCLC
June 4th 2021, 10:52pm
Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the results of subgroup analysis from the phase 2 CodeBreaK 100 trial in patients with KRAS G12C-mutant non–small cell lung cancer.
Ponatinib/Blinatumomab Combo Represents Promising Chemo-Free, HSCT-Sparing Treatment for Ph+ ALL
June 4th 2021, 10:50pm
The efficacy demonstrated with combination of ponatinib and blinatumomab represent a potentially promising chemotherapy-free, hematopoietic stem cell transplant–sparing treatment for patients with Philadelphia chromosome–positive acute lymphocytic leukemia.
Dr. Reck on Updated Results of the CheckMate 9LA Trial in Advanced NSCLC
June 4th 2021, 10:14pm
Martin Reck, MD, PhD, discusses updated results of the phase 3 CheckMate 9LA study in advanced non–small cell lung cancer.
TNO155 Demonstrates Manageable Safety and Consistent SHP2 Inhibition in Advanced Solid Tumors
June 4th 2021, 9:46pm
The investigational SHP2 inhibitor TNO155 demonstrated encouraging safety and tolerability, and consistent evidence of SHP2 inhibition in patients with advanced solid tumors.
Tucatinib Concentrations in CSF Demonstrated in HER2+ Metastatic Breast Cancer
June 4th 2021, 9:41pm
Evidence of tucatinib and its predominant metabolite, ONT-993, were detectable in the cerebrospinal fluid of patients with leptomeningeal metastasis HER2+ positive breast cancer marking a first for tucatinib distribution into the CSF seen in this patient population.